Patents by Inventor Audrey Ragan Odom JOHN

Audrey Ragan Odom JOHN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BREATH BIOMARKERS OF SARS-COV-2 IN CHILDREN AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF COVID-19
    Publication number: 20240081675
    Abstract: Compositions and methods for the diagnosis and treatment of Covid 19 are disclosed.
    Type: Application
    Filed: November 1, 2021
    Publication date: March 14, 2024
    Applicant: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Audrey Ragan ODOM JOHN, Amalia Zoraida BERNA PEREZ, Elikplim AKAHO
  • Alkenyl and beta-substituted phosphonates as antimicrobial agents
    Patent number: 11098072
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions, and methods for treating or preventing microbial infection caused by parasites or bacteria, such as Plasmodium falciparum or related Plasmodium parasite species and Mycobacterium tuberculosis or related Mycobacterium bacteria species. The compounds are ?,?-unsaturated analogs of fosmidomycin and can inhibit deoxyxylulose phosphate reductoisomerase (Dxr) in many microbes, such as P. falciparum.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: August 24, 2021
    Assignees: The George Washington University, A Congressionally Chartered Not-for-Profit Corporation, Washington University, George Mason University, St. Louis University
    Inventors: Cynthia Dowd, Xu Wang, Robert Carl Brothers, Audrey Ragan Odom John, Rachel Edwards, Marvin Meyers, Stacy Arnett, Robin Couch, Kenneth Heidel
  • NOVEL ALKENYL AND BETA-SUBSTITUTED PHROSPHONATES AS ANTIMICROBIAL AGENTS
    Publication number: 20200140469
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions, and methods for treating or preventing microbial infection caused by parasites or bacteria, such as Plasmodium falciparum or related Plasmodium parasite species and Mycobacterium tuberculosis or related Mycobacterium bacteria species. The compounds are ?,?-unsaturated analogs of fosmidomycin and can inhibit deoxyxylulose phosphate reductoisomerase (Dxr) in many microbes, such as P. falciparum.
    Type: Application
    Filed: June 27, 2018
    Publication date: May 7, 2020
    Applicants: The George Washington University, Washington University in St. Louis, George Mason University, Saint Louis University
    Inventors: Cynthia Dowd, Xu WANG, Robert Carl BROTHERS, Audrey Ragan Odom JOHN, Rachel EDWARDS, Marvin MEYERS, Stacy ARNETT, Robin COUCH, Kenneth HEIDEL